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Abstract The antioxidant potential of the dithiol compound
pyrrolidine dithiocarbamate (PDTC) against protein damage
induced by hypochlorous acid (HOCl) was investigated. The
e¡ects of PDTC were compared to those of reduced glutathione
(GSH) and N-acetylcysteine (NAC). PDTC markedly and in a
concentration-dependent manner inhibited HOCl-induced inacti-
vation of K1-antiproteinase, protein carbonyl formation on se-
rum albumin and oxidation of human low-density lipoprotein.
The direct scavenging of HOCl by PDTC was demonstrated by
two quantitative methods, oxidation of ferrocyanide and chlori-
nation of monochlorodimedon. In all assay systems, PDTC was
two to three times more potent than GSH and NAC, while
diethyldithiocarbamate was about as e¡ective as PDTC. These
data demonstrate that PDTC is a potent antioxidant against
HOCl-induced protein oxidative damage, suggesting that
PDTC might be useful in the prevention and treatment of in-
£ammatory conditions.
, 2002 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Activated neutrophils and monocytes generate substantial
amounts of hypochlorous acid (HOCl) via the myeloperoxi-
dase-catalyzed oxidation of chloride ions by hydrogen perox-
ide [1,2]. HOCl is a powerful oxidant capable of oxidizing
many biologically important molecules [3^9], and has been
implicated in emphysema, atherosclerosis and other in£amma-
tory conditions [10,11].
Dithiocarbamates are low-molecular weight thiol com-
pounds that possess a (R1)(R2)N^C(S)^S^R3 functional group
[12]. Pyrrolidine dithiocarbamate (PDTC) and diethyldithio-
carbamate (DDTC) (Scheme 1) are two widely used dithiocar-
bamates in both basic and clinical research [12^26]. Many of
the biological e¡ects of dithiocarbamates are a result of their
metal-chelating properties [12^16].
The biochemistry of dithiocarbamates is of interest because
of their clinical use [12]. There have been a large number of
recent experimental studies, particularly related to regulation
of transcription factors and apoptosis, in which dithiocarba-
mates were used to modify the cellular redox environment
[12,16^26]. Because PDTC can suppress activation of the tran-
scription factor NFUB in response to diverse stimuli, including
reactive oxygen species and HOCl, and is more potent than
the thiol compound N-acetylcysteine (NAC), its mode of ac-
tion was attributed to an antioxidant function [17^26]. How-
ever, the ability of PDTC to scavenge reactive oxygen species
vis-a'-vis its metal-chelating properties is incompletely under-
stood.
PDTC is a stable pyrrolidine derivative of dithiocarbamate
[27]. Since thiol compounds are generally considered to be
e⁄cient HOCl scavengers, the antioxidant e¡ects of PDTC
might be partly due to scavenging of HOCl. Therefore, in
this study, the ability of PDTC to scavenge HOCl was eval-
uated by employing three qualitative, biologically relevant
methods: K1-antiproteinase inactivation, protein carbonyl for-
mation, and low-density lipoprotein (LDL) oxidation; as well
as two quantitative methods: ferrocyanide oxidation and
monochlorodimedon chlorination. The e¡ects of PDTC were
compared to those of reduced glutathione (GSH) and NAC.
2. Materials and methods
2.1. Materials
PDTC, DDTC, GSH, NAC, bovine serum albumin (BSA), HOCl,
K1-antiproteinase, porcine pancreatic elastase, succinyl-(ala)3-p-nitro-
anilide, 2,4-dinitrophenylhydrazine (DNPH), monochlorodimedon,
dimethyl sulfoxide and ferrocyanide were purchased from Sigma (St.
Louis, MO, USA). HOCl was obtained from Aldrich (Milwaukee,
WI, USA). Due to the pKa (7.5) of HOCl [28], it is present at phys-
iological pH as both hypochlorite (OCl3) and HOCl; thus, in this
paper ‘HOCl’ is used to refer to this mixture of OCl3 and HOCl. The
concentration of HOCl present in the diluted commercial NaOCl so-
lution was determined either spectrophotometrically (O292 = 350 M31
cm31) [28], or with the monochlorodimedon method (see below), as-
suming a 1:1 reaction stoichiometry between HOCl and monochloro-
dimedon [9].
2.2. K1-Antiproteinase inactivation
K1-Antiproteinase (400 Wg/ml) was treated with HOCl (10^200 WM)
in the absence or presence of PDTC or GSH (5^200 WM) for 30 min
at 37‡C. K1-Antiproteinase activity was determined following addition
of an equal volume of porcine pancreatic elastase (60 Wg/ml) and 0.1
volume of succinyl-(ala)3-p-nitroanilide (20 mM in dimethyl sulfoxide)
as the colorimetric substrate (O410 = 8800 M31 cm31) [29]. Combina-
tion of equal volumes of K1-antiproteinase and elastase at the concen-
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trations stated above resulted in approximately 75% inhibition of
elastase activity.
2.3. Protein carbonyl formation
BSA (1 mg/ml) was oxidized with HOCl in 0.1 M phosphate bu¡er
(pH 7.4) at 37‡C for 1 h. Protein carbonyls were assayed as described
by Levine et al. [30]. Brie£y, 0.5 ml of 10 mM DNPH in 2 N HCl was
added to 1 ml of the incubation mixture containing BSA and HOCl,
and incubated at room temperature for 1 h. Following addition of 0.5
ml 20% trichloroacetic acid, the samples were incubated on ice for 10
min and centrifuged in a bench-top centrifuge at 3000 rpm for 10 min.
Protein pellets were washed three times with 3 ml ethanol:ethyl ace-
tate (1:1, v/v) and dissolved in 6 M guanidine (pH 2.3). The peak
absorbance at 370 nm was used to quantitate protein carbonyls, and
the data were expressed as nmol carbonyl groups per mg of protein,
using a molar absorption coe⁄cient of 22 000 M31 cm31 for the
DNPH derivatives [30].
2.4. LDL oxidation
LDL was isolated from fresh human plasma by sequential centri-
fugation [31], modi¢ed as described previously [32]. Isolated LDL
(1.0196 d6 1.067 g/ml) was desalted by two sequential passages
through PD-10 gel ¢ltration columns (Pharmacia Biotech, Uppsala,
Sweden). Total protein was estimated using a Lowry Micro Method
Kit (Sigma P5656). For experiments, LDL was diluted to a concen-
tration of 0.5 mg protein/ml (W1 WM LDL) in phosphate-bu¡ered
saline (10 mM phosphate, 140 mM NaCl, pH 7.4) containing the
metal chelator diethylenetriaminepentaacetic acid (100 WM).
HOCl (100^500 WM) was added to LDL (0.5 mg protein/ml) with
rapid, gentle mixing, and the samples were incubated for 30 min at
37‡C. PDTC or NAC (25^200 WM) were added to LDL together with
HOCl.
The change in the relative electrophoretic mobility (REM) of LDL
was determined by agarose gel electrophoresis using a Paragon Lipo-
protein Electrophoresis Kit (Beckman), as described previously [32].
LDL lysine residues were measured following derivatization with £u-
orescamine, as described previously [32].
2.5. Ferrocyanide oxidation
The oxidation of Fe(II)(CN)6 (10 mM) by HOCl (0.2 mM) in 0.1 M
phosphate bu¡er (pH 7.4) was employed as a reference reaction to
investigate the stoichiometry of the reaction of HOCl with PDTC [33].
PDTC or GSH was incubated with HOCl for 5 min before the addi-
tion of Fe(II)(CN)6. The absorbance of Fe(II)(CN)6 was monitored at
420 nm (O=1050 M31 cm31). Under these conditions, two molecules
of Fe(II)(CN)6 were oxidized by one molecule of HOCl within 5 min
[33]. The inhibition of oxidation was calculated from the di¡erence in
absorbance in the presence and absence of various concentrations of
PDTC or GSH.
2.6. Monochlorodimedon chlorination
Monochlorodimedon chlorination was measured directly by moni-
toring absorbance at 290 nm (O=19 900 M31 cm31) [9] of a 50 WM
monochlorodimedon solution containing 0.2 mM HOCl. HOCl was
added slowly to 1 ml of monochlorodimedon in 0.1 M phosphate
bu¡er (pH 7.4), which was continuously vortex-mixed during the ad-
dition. Absorbance of each solution was read 5 min later. The inhi-
bition of chlorination was calculated from the di¡erence in absor-
bance in the presence and absence of various concentrations of
PDTC or GSH.
3. Results and discussion
3.1. K1-Antiproteinase inactivation
HOCl is a strong oxidant released from activated phago-
cytes that readily reacts with amino acid residues in proteins,
in particular methionine, cysteine and lysine. A prominent
e¡ect of HOCl at sites of in£ammation is inactivation of the
protease inhibitor K1-antiproteinase. Due to this inactivation,
the ability of K1-antiproteinase to inhibit elastase is lost. The
resulting higher activity of elastase has been implicated in
tissue degradation underlying, e.g., lung emphysema. The ex-
tent of K1-antiproteinase inactivation by HOCl in the presence
of various scavengers has been used to quantify their antioxi-
dant potency [29,34,35].
As shown in Fig. 1A, addition of HOCl (10^200 WM) to K1-
antiproteinase (400 Wg/ml) dose-dependently impaired the
ability of K1-antiproteinase to inhibit elastase. This inactiva-
tion of K1-antiproteinase by HOCl was markedly attenuated
by PDTC (100 WM) (Fig. 1A). The dose dependence of the
protective e¡ect of PDTC was investigated using 50 WM
HOCl, a concentration at which K1-antiproteinase was inacti-
vated by about 90% (Fig. 1A). As shown in Fig. 1B, PDTC
(10^200 WM) e¡ectively and dose-dependently prevented inac-
tivation of K1-antiproteinase. The concentration required for
50% inhibition (IC50) of HOCl-induced inactivation of K1-
Scheme 1. Chemical structures of PDTC and DDTC.
Fig. 1. A: Concentration-dependent inactivation of K1-antiproteinase (400 Wg/ml) by HOCl (b), and inhibition by 100 WM PDTC (R). B: Con-
centration-dependent protection by PDTC (R) and GSH (F) against inactivation of K1-antiproteinase by 50 WM HOCl. K1-Antiproteinase ac-
tivity was measured as described in Section 2. The horizontal line in panel B indicates 50% inhibition. Data represent the meanSS.D. of three
separate experiments.
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antiproteinase was used to compare the scavenging potency of
PDTC with GSH, a major intracellular, water-soluble antioxi-
dant. Based on this measure, PDTC was about three-fold
more potent than GSH (IC50 = 13 WM PDTC and 38 WM
GSH) (Fig. 1B).
The protection by PDTC was not due to regeneration of
K1-antiproteinase after it had been inactivated by HOCl, since
addition of 100 WM PDTC to inactivated K1-antiproteinase
did not restore the inhibitory e¡ect of K1-antiproteinase on
elastase (data not shown). Therefore, the most likely mecha-
nism by which PDTC exerts its protective e¡ect is direct scav-
enging of HOCl before it can react with and inactivate K1-
antiproteinase.
3.2. Protein carbonyl formation
Oxidative damage to proteins results in the formation of
protein carbonyl groups [30]. Increased tissue protein carbon-
yls have been detected in numerous human diseases, such as
rheumatoid arthritis, myocardial ischemia-reperfusion injury
and Alzheimer’s disease [30]. The amount of carbonyl groups
formed on proteins re£ects the extent of oxidative damage.
Therefore, we measured carbonyl formation on BSA, used
as a model protein, to test the ability of PDTC to scavenge
HOCl.
As shown in Fig. 2A, the carbonyl content of BSA (1 mg/
ml) increased linearly upon incubation with increasing con-
centrations of HOCl (250 WM to 1 mM). PDTC (500 WM)
completely inhibited HOCl-induced carbonyl formation (Fig.
2A). As above, a ¢xed concentration of HOCl (1 mM) was
used to determine the IC50 for PDTC and GSH. As shown in
Fig. 2B, PDTC was about 2.3-fold more potent in scavenging
HOCl than GSH (IC50 = 70 WM PDTC and 160 WM GSH).
3.3. LDL oxidation
Oxidation of LDL and increased negative surface charge
due to modi¢cation of its protein moiety, apolipoprotein
B-100 (apoB), have been implicated in increased macrophage
uptake of LDL and formation of lipid-laden foam cells in
human atherosclerotic lesions [36,37]. Exposure of LDL to
increasing concentrations of HOCl (100^500 WM) resulted in
a dose-dependent increase in its electronegative charge, as
measured by REM, with a greater than 200% increase at
Fig. 2. A: Concentration-dependent formation of protein carbonyls in BSA (1 mg/ml) by HOCl (b), and inhibition by 500 WM PDTC (R).
B: Concentration-dependent protection by PDTC (R) and GSH (F) against protein carbonyl formation in BSA by 1 mM HOCl. BSA carbon-
yl content was measured as described in Section 2. The horizontal line in panel B indicates 50% inhibition. Data represent the mean of three
separate experiments, with S.D. less than 5%.
Fig. 3. A: Concentration-dependent increase in REM of LDL incubated with HOCl (b), and inhibition by 50 WM PDTC (F) and NAC (9).
B: Concentration-dependent protection by PDTC (b) and NAC (9) against increased REM of LDL incubated with 500 WM HOCl. REM of
LDL was determined as described in Section 2. The horizontal line in panel B indicates 50% inhibition. Data represent the meanSS.D. of three
separate experiments.
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500 WM HOCl (Fig. 3A). The extent of LDL oxidation mea-
sured by REM was not linearly correlated with HOCl con-
centration (Fig. 3A), most likely because HOCl can react with
a number of di¡erent amino acid residues with di¡erent a⁄n-
ities, and oxidation of these amino acids results in di¡erent
e¡ects on the electronegative charge of the lipoprotein par-
ticle. In the presence of 50 WM PDTC or NAC, 500 WM HOCl
caused only a 60% or 170% increase in REM, respectively
(Fig. 3A). The increase in REM correlated with the loss of
LDL lysine residues: 500 WM HOCl caused oxidation of 76%
of the lysine residues in apoB, whereas in the presence of 50
WM PDTC or NAC only 34% and 58%, respectively, of the
lysine residues became oxidized (data not shown). Exposure of
LDL to 500 WM HOCl in the presence of increasing concen-
trations of PDTC or NAC (25^200 WM) resulted in a dose-
dependent decrease in REM, with IC50 values of 31 WM
PDTC and 80 WM NAC (Fig. 3B). These IC50 values were
similar to those for inhibition of lysine oxidation, viz. 41 WM
PDTC and 80 WM NAC (data not shown). Thus, PDTC is at
least twice as e¡ective as NAC in protecting against HOCl-
mediated apoB modi¢cation in LDL.
3.4. Ferrocyanide oxidation and monochlorodimedon
chlorination
The ability of PDTC to scavenge HOCl was further eval-
uated by two quantitative methods. The oxidation of ferro-
cyanide, Fe(II)(CN)6, by HOCl (200 WM) was used to deter-
mine the stoichiometry of the reaction of HOCl with PDTC
[33]. Based on this quantitative method, one molecule of
PDTC was able to scavenge up to 11 molecules of HOCl,
while one molecule of GSH was able to scavenge only four
molecules of HOCl (Fig. 4). Identical stoichiometries for the
reaction of HOCl with PDTC and GSH were obtained by
employing the monochlorodimedon chlorination assay [9]
(data not shown). Thus, PDTC appears to be a very potent
HOCl scavenger. At present we cannot explain why one mol-
ecule of PDTC was able to scavenge up to 11 molecules of
HOCl. Further studies are needed to explain this extraordi-
nary result.
Virtually identical dose-dependent e¡ects were observed
with another dithiocarbamate, DDTC, against ferrocyanide
oxidation and monochlorodimedon chlorination, as well as
K1-antiproteinase inactivation, BSA carbonyl formation and
LDL oxidation (data not shown).
3.5. Direct interaction between PDTC and HOCl
To better understand the mechanism by which PDTC scav-
enges HOCl, the direct interaction between these two com-
pounds was studied. PDTC possesses two distinct UV absor-
bance peaks at 254 and 278 nm, which correspond to the
dithiocarbamate group. Addition of HOCl (100^600 WM) to
PDTC (100 WM) led to a dose-dependent decay and disap-
pearance of these two peaks (Fig. 5). Similar e¡ects were also
observed with DDTC (data not shown). These results indicate
that the dithiocarbamate group of PDTC is responsible for its
HOCl scavenging ability.
At low HOCl:PDTC ratios (9 2), PDTC was oxidized by
HOCl to form a white precipitate, which was tentatively iden-
ti¢ed as its corresponding disul¢de based on mass spectromet-
ric analysis (data not shown) and previous studies on other
dithiocarbamates [38]. The precipitate could be further oxi-
dized by excess HOCl to form several as yet unidenti¢ed
products (Fig. 5).
3.6. Summary
In this study, the ability of the dithiocarbamates, PDTC
and DDTC, to scavenge HOCl was carefully evaluated by
employing three qualitative, biologically relevant methods:
K1-antiproteinase inactivation, protein carbonyl formation
and LDL oxidation; and two quantitative methods: ferrocya-
nide oxidation and monochlorodimedon chlorination.
Although these ¢ve test systems use di¡erent parameters to
assess the ability to scavenge HOCl, PDTC and DDTC were
consistently found to be two to three times more potent than
Fig. 4. Concentration-dependent inhibition by PDTC (R) and GSH
(F) of HOCl-induced oxidation of Fe(II)(CN)6. Ferrocyanide oxida-
tion was measured as described in Section 2. Relative absorbance
changes at 420 nm vAThiol/vAControl are plotted against the concen-
tration ratio of [Thiol]:[HOCl]. vAThiol =AThiol (with HOCl)3AThiol
(without HOCl). Data represent the mean of three separate experi-
ments, with S.D. less than 5%.
Fig. 5. Destruction of the dithiocarbamate group of PDTC by
HOCl. PDTC (100 WM) was incubated without (A) or with HOCl
(B^F) in 0.1 M phosphate bu¡er (pH 7.4) at room temperature for
5 min, and absorbance was recorded from 220 to 320 nm. HOCl
concentrations (WM) were as follows: curve B, 100; curve C, 200;
curve D, 300; curve E, 400; and curve F, 600.
FEBS 26757 19-11-02
B.-Z. Zhu et al./FEBS Letters 532 (2002) 80^84 83
GSH or NAC. As far as we know, this is the ¢rst report to
show that these dithiocarbamates are potent HOCl scav-
engers. PDTC has been shown to suppress NFUB activation
after HOCl stimulation in a T-lymphocytic cell line [25]. This
e¡ect was attributed to the general antioxidant activity of
PDTC [25]. Based on our new ¢ndings, we propose that the
protection by PDTC is through direct scavenging of HOCl.
Because HOCl has been implicated in emphysema, atheroscle-
rosis and many other in£ammatory-immune injuries [1,2] and
dithiocarbamates are already used clinically [12,39^41], in vivo
studies in humans of the potential of dithiocarbamates to
prevent or treat in£ammatory conditions appear warranted.
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